Louis Falo

  • Balmert, S.C., Ghozloujeh, Z.G., Carey, C.D., Akilov, O.E., Korkmaz, E., & Falo, L.D. (2021). Research Techniques Made Simple: Skin-Targeted Drug and Vaccine Delivery Using Dissolvable Microneedle Arrays. J Invest Dermatol, 141(11), 2549-2557.e1.Elsevier. doi: 10.1016/j.jid.2021.07.177.
  • Hao, X., Falo Iii, L.D., Chen, G., Zhang, J., Carey, C.D., Storkus, W.J., Falo, L.D., & You, Z. (2021). Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors. J Immunother Cancer, 9(1).BMJ. doi: 10.1136/jitc-2020-001179.
  • Kim, E., Weisel, F.J., Balmert, S.C., Khan, M.S., Huang, S., Erdos, G., Kenniston, T.W., Carey, C.D., Joachim, S.M., Conter, L.J., Weisel, N.M., Okba, N.M.A., Haagmans, B.L., Percivalle, E., Cassaniti, I., Baldanti, F., Korkmaz, E., Shlomchik, M.J., Falo, L.D., & Gambotto, A. (2021). A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. Eur J Immunol, 51(7), 1774-1784.Wiley. doi: 10.1002/eji.202149167.
  • Korkmaz, E., Balmert, S.C., Sumpter, T.L., Carey, C.D., Erdos, G., & Falo, L.D. (2021). Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev, 171, 164-186.Elsevier. doi: 10.1016/j.addr.2021.01.022.
  • Balmert, S.C., Carey, C.D., Falo, G.D., Sethi, S.K., Erdos, G., Korkmaz, E., & Falo, L.D. (2020). Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release, 317, 336-346.Elsevier. doi: 10.1016/j.jconrel.2019.11.023.
  • Erdos, G., Balmert, S.C., Carey, C.D., Falo, G.D., Patel, N.A., Zhang, J., Gambotto, A., Korkmaz, E., & Falo, L.D. (2020). Improved Cutaneous Genetic Immunization by Microneedle Array Delivery of an Adjuvanted Adenovirus Vaccine. J Invest Dermatol, 140(12), 2528-2531.e2.Elsevier. doi: 10.1016/j.jid.2020.03.966.
  • Falo, L.D. (2020). Advances in skin science enable the development of a COVID-19 vaccine. J Am Acad Dermatol, 83(4), 1226-1227.Elsevier. doi: 10.1016/j.jaad.2020.05.126.
  • Kim, E., Erdos, G., Huang, S., Kenniston, T.W., Balmert, S.C., Carey, C.D., Raj, V.S., Epperly, M.W., Klimstra, W.B., Haagmans, B.L., Korkmaz, E., Falo, L.D., & Gambotto, A. (2020). Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine, 55, 102743.Elsevier. doi: 10.1016/j.ebiom.2020.102743.
  • Korkmaz, E., & Falo, L.D. (2020). Spherical Nucleic Acids as Emerging Topical Therapeutics: A Focus on Psoriasis. J Invest Dermatol, 140(2), 278-281.Elsevier. doi: 10.1016/j.jid.2019.07.683.
  • Shurin, G.V., Kruglov, O., Ding, F., Lin, Y., Hao, X., Keskinov, A.A., You, Z., Lokshin, A.E., LaFramboise, W.A., Falo, L.D., Shurin, M.R., & Bunimovich, Y.L. (2019). Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Res, 79(10), 2736-2747.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-18-3872.
  • Brand, R.M., Wipf, P., Durham, A., Epperly, M.W., Greenberger, J.S., & Falo, L.D. (2018). Targeting Mitochondrial Oxidative Stress to Mitigate UV-Induced Skin Damage. Front Pharmacol, 9(AUG), 920.Frontiers. doi: 10.3389/fphar.2018.00920.
  • Diaz-Perez, J.A., Killeen, M.E., Yang, Y., Carey, C.D., Falo, L.D., & Mathers, A.R. (2018). Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol, 138(12), 2595-2605.Elsevier. doi: 10.1016/j.jid.2018.05.018.
  • Duangkhae, P., Erdos, G., Ryman, K.D., Watkins, S.C., Falo, L.D., Marques, E.T.A., & Barratt-Boyes, S.M. (2018). Interplay between Keratinocytes and Myeloid Cells Drives Dengue Virus Spread in Human Skin. J Invest Dermatol, 138(3), 618-626.Elsevier. doi: 10.1016/j.jid.2017.10.018.
  • Epperly, M.W., Wipf, P., Fisher, R., Franicola, D., Beumer, J., Li, S., Brand, R.M., Falo, L.D., Erdos, G., & Greenberger, J.S. (2018). Evaluation of Different Formulations and Routes for the Delivery of the Ionizing Radiation Mitigator GS-Nitroxide (JP4-039). In Vivo, 32(5), 1009-1023.Anticancer Research USA. doi: 10.21873/invivo.11341.
  • Geskin, L.J., Akilov, O.E., Kwon, S., Schowalter, M., Watkins, S., Whiteside, T.L., Butterfield, L.H., & Falo, L.D. (2018). Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother, 67(3), 423-434.Springer Nature. doi: 10.1007/s00262-017-2090-z.
  • Geskin, L.J., Akilov, O.E., Schowalter, M.K., & Falo, L.D. (2018). Interferon-α2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides. Cancer Immunol Immunother, 67(7), 1177-1178.Springer Nature. doi: 10.1007/s00262-018-2156-6.
  • Geskin, L.J., Damiano, J.J., Patrone, C.C., Butterfield, L.H., Kirkwood, J.M., & Falo, L.D. (2018). Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res, 28(3), 211-221.Wolters Kluwer. doi: 10.1097/CMR.0000000000000441.
  • Hoot, J.W., Douglas, J.D., & Falo, L.D. (2018). Patch Testing in a Patient on Dupilumab. Dermatitis, 29(3), 164.SAGE Publications. doi: 10.1097/DER.0000000000000357.
  • Mathers, A.R., Carey, C.D., Killeen, M.E., Salvatore, S.R., Ferris, L.K., Freeman, B.A., Schopfer, F.J., & Falo, L.D. (2018). Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation. Free Radic Biol Med, 115, 31-42.Elsevier. doi: 10.1016/j.freeradbiomed.2017.11.009.
  • Zhang, Y., Liu, Z., Hao, X., Li, A., Zhang, J., Carey, C.D., Falo, L.D., & You, Z. (2018). Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother, 67(3), 353-366.Springer Nature. doi: 10.1007/s00262-017-2087-7.
  • Balmert, S.C., Donahue, C., Vu, J.R., Erdos, G., Falo, L.D., & Little, S.R. (2017). In vivo induction of regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis. J Control Release, 261, 223-233.Elsevier. doi: 10.1016/j.jconrel.2017.07.006.
  • Brand, R.M., Epperly, M.W., Stottlemyer, J.M., Skoda, E.M., Gao, X., Li, S., Huq, S., Wipf, P., Kagan, V.E., Greenberger, J.S., & Falo, L.D. (2017). A Topical Mitochondria-Targeted Redox-Cycling Nitroxide Mitigates Oxidative Stress-Induced Skin Damage. J Invest Dermatol, 137(3), 576-586.Elsevier. doi: 10.1016/j.jid.2016.09.033.
  • Liu, Z., Hao, X., Zhang, Y., Zhang, J., Carey, C.D., Falo, L.D., Storkus, W.J., & You, Z. (2017). Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity. Oncoimmunology, 6(6), e1315487.Taylor & Francis. doi: 10.1080/2162402X.2017.1315487.
  • Mathers, A.R., Carey, C.D., Killeen, M.E., Diaz-Perez, J.A., Salvatore, S.R., Schopfer, F.J., Freeman, B.A., & Falo, L.D. (2017). Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. Allergy, 72, (pp. 656-664).Wiley.Denmark. doi: 10.1111/all.13067.
  • Mathers, A.R., Carey, C.D., Killeen, M.E., Diaz-Perez, J.A., Salvatore, S.R., Schopfer, F.J., Freeman, B.A., & Falo, L.D. (2017). Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. ALLERGY, 72(4), 656-664.Wiley. doi: 10.1111/all.13067.
  • Kim, E., Erdos, G., Huang, S., Kenniston, T., Falo, L.D., & Gambotto, A. (2016). Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine, 13, 315-320.Elsevier. doi: 10.1016/j.ebiom.2016.09.028.
  • Korkmaz, E., Friedrich, E.E., Ramadan, M.H., Erdos, G., Mathers, A.R., Ozdoganlar, O.B., Washburn, N.R., & Falo, L.D. (2016). Tip-Loaded Dissolvable Microneedle Arrays Effectively Deliver Polymer-Conjugated Antibody Inhibitors of Tumor-Necrosis-Factor-Alpha Into Human Skin. J Pharm Sci, 105(11), 3453-3457.Elsevier. doi: 10.1016/j.xphs.2016.07.008.
  • Brand, R.M., Stottlemyer, J.M., Cline, R.A., Donahue, C., Behari, J., & Falo, L.D. (2015). Skin Immunization Obviates Alcohol-Related Immune Dysfunction. Biomolecules, 5(4), 3009-3028.MDPI. doi: 10.3390/biom5043009.
  • Calhoun, S. (2015). Concierge medicine: incorporating components into your healthcare system. University of Pittsburgh.
  • Dulmage, B.O., Akilov, O., Vu, J.R., Falo, L.D., & Geskin, L.J. (2015). Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget, 10(33), 3104-3113.Impact Journals. doi: 10.18632/oncotarget.5742.
  • Dulmage, B.O., Story, S.K., Falo, L.D., & Geskin, L.J. (2015). Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma. Leuk Lymphoma, 56(7), 2225-2227.Taylor & Francis. doi: 10.3109/10428194.2014.995649.
  • Erdos, G., Korkmaz, E., Friedrich, E., Ramadan, M., Mathers, A.R., Ozdoganlar, B., Washburn, N., & Falo, L.D. (2015). Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 135, (p. S94).
  • Korkmaz, E., Friedrich, E.E., Ramadan, M.H., Erdos, G., Mathers, A.R., Burak Ozdoganlar, O., Washburn, N.R., & Falo, L.D. (2015). Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. Acta Biomater, 24, 96-105.Elsevier. doi: 10.1016/j.actbio.2015.05.036.
  • Zhang, Y., Chen, G., Liu, Z., Tian, S., Zhang, J., Carey, C.D., Murphy, K.M., Storkus, W.J., Falo, L.D., & You, Z. (2015). Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. J Immunol, 194(12), 5937-5947.Oxford University Press (OUP). doi: 10.4049/jimmunol.1500089.
  • Bediz, B., Korkmaz, E., Khilwani, R., Donahue, C., Erdos, G., Falo, L.D., & Ozdoganlar, O.B. (2014). Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application. Pharm Res, 31(1), 117-135.Springer Nature. doi: 10.1007/s11095-013-1137-x.
  • Rothstein, S.N., Donahue, C., Falo, L.D., & Little, S.R. (2014). In silico programming of degradable microparticles to hide and then reveal immunogenic payloads in vivo. J Mater Chem B, 2(37), 6183-6187.Royal Society of Chemistry (RSC). doi: 10.1039/c4tb01042f.
  • Schowalter, M.K., Dulmage, B.O., Ho, J., Vu, J.R., Falo, L.D., & Geskin, L.J. (2014). Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res, 24(4), 397-400.Wolters Kluwer. doi: 10.1097/CMR.0000000000000070.
  • Sumpter, T.L., & Falo, L.D. (2014). "Toll"-erance in the skin. Immunity, 41(5), 677-679.Elsevier. doi: 10.1016/j.immuni.2014.11.003.
  • Zhang, Y., Tian, S., Liu, Z., Zhang, J., Zhang, M., Bosenberg, M.W., Kedl, R.M., Waldmann, T.A., Storkus, W.J., Falo, L.D., & You, Z. (2014). Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology, 3(10), e959321.Taylor & Francis. doi: 10.4161/21624011.2014.959321.
  • Ferris, L.K., Mburu, Y.K., Mathers, A.R., Fluharty, E.R., Larregina, A.T., Ferris, R.L., & Falo, L.D. (2013). Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol, 133, (pp. 460-468).Elsevier.United States. doi: 10.1038/jid.2012.319.
  • Janelsins, B.M., Sumpter, T.L., Tkacheva, O.A., Rojas-Canales, D.M., Erdos, G., Mathers, A.R., Shufesky, W.J., Storkus, W.J., Falo, L.D., Morelli, A.E., & Larregina, A.T. (2013). Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood, 121(15), 2923-2933.American Society of Hematology. doi: 10.1182/blood-2012-07-446054.
  • Killeen, M.E., Ferris, L., Kupetsky, E.A., Falo, L., & Mathers, A.R. (2013). Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol, 190(8), 4324-4336.Oxford University Press (OUP). doi: 10.4049/jimmunol.1202045.
  • Mirvish, J.J., Pomerantz, R.G., Falo, L.D., & Geskin, L.J. (2013). Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol, 31(4), 423-431.Elsevier. doi: 10.1016/j.clindermatol.2013.01.009.
  • Akilov, O.E., Wu, M.X., Ustyugova, I.V., Falo, L.D., & Geskin, L.J. (2012). Resistance of Sézary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression. Exp Dermatol, 21(4), 287-292.Wiley. doi: 10.1111/j.1600-0625.2012.01452.x.
  • Tian, S., Liu, Z., Donahue, C., Falo, L.D., & You, Z. (2012). Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther, 20(2), 432-442.Elsevier. doi: 10.1038/mt.2011.183.
  • Akilov, O.E., Wu, M.X., Jin, Y., Zhou, Z., Geskin, L.J., Falo, L.D., & Hasan, T. (2011). Vaccination with photodynamic therapy-treated macrophages induces highly suppressive T-regulatory cells. Photodermatol Photoimmunol Photomed, 27(2), 97-107.Wiley. doi: 10.1111/j.1600-0781.2011.00578.x.
  • Liu, Z., Falo, L.D., & You, Z. (2011). Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol, 187(1), 118-125.Oxford University Press (OUP). doi: 10.4049/jimmunol.1003378.
  • Pomerantz, R.G., Mirvish, E.D., Erdos, G., Falo, L.D., & Geskin, L.J. (2010). Novel approach to gene expression profiling in Sézary syndrome. Br J Dermatol, 163(5), 1090-1094.Oxford University Press (OUP). doi: 10.1111/j.1365-2133.2010.09973.x.
  • Liu, Z., Kim, J.H., Falo, L.D., & You, Z. (2009). Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol, 182(10), 6160-6167.Oxford University Press (OUP). doi: 10.4049/jimmunol.0802664.
  • Liu, Z., Tian, S., Falo, L.D., Sakaguchi, S., & You, Z. (2009). Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther, 17(7), 1274-1281.Elsevier. doi: 10.1038/mt.2009.100.
  • Liu, Z., Tian, S., Falo, L.D., Sakaguchi, S., & You, Z. (2009). Therapeutic Immunity by Adoptive Tumor-primed CD4(+) T-cell Transfer in Combination With In Vivo GITR Ligation. Mol Ther, 17(7), 1274-1281. doi: 10.1038/mt.2009.100.
  • Mirvish, E.D., Pomerantz, R.G., Falo, L.D., & Geskin, L.J. (2009). Dendritic Cell Vaccines in Cancer: Obstaclesto Overcome. In Dendritic Cells in Cancer. (pp. 309-330).Springer Nature. doi: 10.1007/978-0-387-88611-4_21.
  • Sasaki, K., Pardee, A.D., Qu, Y., Zhao, X., Ueda, R., Kohanbash, G., Bailey, L.M., Okada, H., Muthuswamy, R., Kalinski, P., Basse, P.H., Falo, L.D., & Storkus, W.J. (2009). IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother, 32(8), 793-802.Wolters Kluwer. doi: 10.1097/CJI.0b013e3181acec1e.
  • Tian, S., Liu, Z., Donahue, C., Noh, H.S., Falo, L.D., & You, Z. (2009). Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther, 16(10), 1260-1270.Springer Nature. doi: 10.1038/gt.2009.110.
  • Liu, Z., Noh, H.S., Chen, J., Kim, J.H., Falo, L.D., & You, Z. (2008). Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol, 181(6), 4363-4370.Oxford University Press (OUP). doi: 10.4049/jimmunol.181.6.4363.
  • Pomerantz, R.G., Chirinos, R.E., Falo, L.D., & Geskin, L.J. (2008). Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol, 144(7), 949-950.American Medical Association (AMA). doi: 10.1001/archderm.144.7.949.
  • He, Y., & Falo, L.D. (2007). Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther, 9(5), 439-446.
  • He, Y., Munn, D., & Falo, L.D. (2007). Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines, 6(6), 913-924.Taylor & Francis. doi: 10.1586/14760584.6.6.913.
  • Mathers, A.R., Morelli, A.E., Janesins, B., Rubin, J.P., Tkacheva, O.A., Falo, L.D.J., & Larregina, A.T. (2007). Human skin migratory dendritic cells that do not secrete IL-12p70 stimulate both Th17 and Th1 allogeneic responses. JOURNAL OF IMMUNOLOGY, 178.Oxford University Press (OUP). doi: 10.4049/jimmunol.178.supp.36.20.
  • Morelli, A.E., Tkacheva, O.A., Janelsins, B., Mathers, A.R., Shufeski, W.J., Rubin, J.P., Falo, L.D., & Larregina, A.T. (2007). Following the emigration of Langerhans cells, the epidermis of human skin is colonized by dermal-resident CD14+cells, which acquire the phenotype of Langerhans cells. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 127, (p. S121).
  • Nakamura, Y., Watchmaker, P., Urban, J., Sheridan, B., Giermasz, A., Nishimura, F., Sasaki, K., Cumberland, R., Muthuswamy, R., Mailliard, R.B., Larregina, A.T., Falo, L.D., Gooding, W., Storkus, W.J., Okada, H., Hendricks, R.L., & Kalinski, P. (2007). Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res, 67(20), 10012-10018.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-07-1735.
  • Storkus, W.J., & Falo, L.D. (2007). A 'good death' for tumor immunology. Nat Med, 13(1), 28-30.Springer Nature. doi: 10.1038/nm0107-28.
  • Ferris, L., Fluharty, E., & Falo, L.D. (2006). Human beta defensin 3 induces maturation of human monocyte-derived dendritic cells. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, 123.
  • He, Y., & Falo, L.D. (2006). Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector. Immunol Res, 36(1-3), 101-117.Springer Nature. doi: 10.1385/IR:36:1:101.
  • He, Y., Zhang, J., Donahue, C., & Falo, L.D. (2006). Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity, 24(5), 643-656.Elsevier. doi: 10.1016/j.immuni.2006.03.014.
  • Nayak, J.V., Hokey, D.A., Larregina, A., He, Y., Salter, R.D., Watkins, S.C., & Falo, L.D. (2006). Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J Immunol, 177(12), 8493-8503.Oxford University Press (OUP). doi: 10.4049/jimmunol.177.12.8493.
  • Vangasseri, D.P., Cui, Z., Chen, W., Hokey, D.A., Falo, L.D., & Huang, L. (2006). Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol, 23(5), 385-395.Taylor & Francis. doi: 10.1080/09687860600790537.
  • He, Y., Zhang, J., Mi, Z., Robbins, P., & Falo, L.D. (2005). Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol, 174(6), 3808-3817.Oxford University Press (OUP). doi: 10.4049/jimmunol.174.6.3808.
  • Hokey, D.A., Larregina, A.T., Erdos, G., Watkins, S.C., & Falo, L.D. (2005). Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res, 65(21), 10059-10067.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-05-1692.
  • Kalinski, P., Mailliard, R.B., Geskin, L., Giermasz, A., Nakamura, Y., Storkus, W.J., Lotze, M.T., Bartlett, D.L., Kirkwood, J.M., & Falo, L.D. (2005). Polarized DC1-based therapeutic cancer vaccines. JOURNAL OF IMMUNOTHERAPY, 28(6), 656.Wolters Kluwer. doi: 10.1097/01.cji.0000191090.97275.78.
  • Kim, J.H., Chen, J., Majumder, N., Lin, H., Falo, L.D., & You, Z. (2005). 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther, 12(20), 1517-1525.Springer Nature. doi: 10.1038/sj.gt.3302584.
  • Kim, J.H., Majumder, N., Lin, H., Chen, J., Falo, L.D., & You, Z. (2005). Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther, 11(6), 941-949.Elsevier. doi: 10.1016/j.ymthe.2005.01.003.
  • Kim, J.H., Majumder, N., Lin, H., Watkins, S., Falo, L.D., & You, Z. (2005). Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther, 16(11), 1255-1266.SAGE Publications. doi: 10.1089/hum.2005.16.1255.
  • Larregina, A.T., & Falo, L.D. (2005). Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol, 124(1), 1-12.Elsevier. doi: 10.1111/j.1523-1747.2004.23554.x.
  • Morelli, A.E., Peter Rubin, J., Erdos, G., Tkacheva, O.A., Mathers, A.R., Zahorchak, A.F., Thomson, A.W., Falo, L.D., & Larregina, A.T. (2005). CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. Journal of Immunology, 175(12), 7905-7915. doi: 10.4049/jimmunol.175.12.7905.
  • Morelli, A.E., Rubin, J.P., Erdos, G., Tkacheva, O.A., Mathers, A.R., Zahorchak, A.F., Thomson, A.W., Falo, L.D., & Larregina, A.T. (2005). CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol, 175(12), 7905-7915.Oxford University Press (OUP). doi: 10.4049/jimmunol.175.12.7905.
  • Larregina, A.T., Morelli, A.E., Tkacheva, O., Erdos, G., Donahue, C., Watkins, S.C., Thomson, A.W., & Falo, L.D. (2004). Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood, 103(3), 811-819.American Society of Hematology. doi: 10.1182/blood-2003-02-0524.
  • Morel, P.A., Falkner, D., Plowey, J., Larregina, A.T., & Falo, L.D. (2004). DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine, 22(3-4), 447-456.Elsevier. doi: 10.1016/j.vaccine.2003.07.012.
  • Morelli, A.E., Larregina, A.T., Shufesky, W.J., Sullivan, M.L.G., Stolz, D.B., Papworth, G.D., Zahorchak, A.F., Logar, A.J., Wang, Z., Watkins, S.C., Falo, L.D., & Thomson, A.W. (2004). Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood, 104(10), 3257-3266.American Society of Hematology. doi: 10.1182/blood-2004-03-0824.
  • Dileo, J., Banerjee, R., Whitmore, M., Nayak, J.V., Falo, L.D., & Huang, L. (2003). Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther, 7(5 Pt 1), 640-648.Elsevier. doi: 10.1016/s1525-0016(03)00064-9.
  • Morelli, A.E., Larregina, A.T., Shufesky, W.J., Zahorchak, A.F., Logar, A.J., Papworth, G.D., Wang, Z., Watkins, S.C., Falo, L.D., & Thomson, A.W. (2003). Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood, 101(2), 611-620.American Society of Hematology. doi: 10.1182/blood-2002-06-1769.
  • Lui, V.W.Y., He, Y., Falo, L., & Huang, L. (2002). Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther, 13(2), 177-185.SAGE Publications. doi: 10.1089/10430340252769716.
  • Zimmer, M.I., Larregina, A.T., Castillo, C.M., Capuano, S., Falo, L.D., Murphey-Corb, M., Reinhart, T.A., & Barratt-Boyes, S.M. (2002). Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood, 99(8), 2859-2868.American Society of Hematology. doi: 10.1182/blood.v99.8.2859.
  • Hackstein, H., Morelli, A.E., Larregina, A.T., Ganster, R.W., Papworth, G.D., Logar, A.J., Watkins, S.C., Falo, L.D., & Thomson, A.W. (2001). Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol, 166(12), 7053-7062.Oxford University Press (OUP). doi: 10.4049/jimmunol.166.12.7053.
  • Larregina, A.T., Morelli, A.E., Spencer, L.A., Logar, A.J., Watkins, S.C., Thomson, A.W., & Falo, L.D. (2001). Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol, 2(12), 1151-1158.Springer Nature. doi: 10.1038/ni731.
  • Larregina, A.T., Watkins, S.C., Erdos, G., Spencer, L.A., Storkus, W.J., Beer Stolz, D., & Falo, L.D. (2001). Direct transfection and activation of human cutaneous dendritic cells. Gene Ther, 8(8), 608-617.Springer Nature. doi: 10.1038/sj.gt.3301404.
  • Lui, V.W., Falo, L.D., & Huang, L. (2001). Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J Gene Med, 3(4), 384-393.Wiley. doi: 10.1002/jgm.201.
  • Morelli, A.E., Zahorchak, A.F., Larregina, A.T., Colvin, B.L., Logar, A.J., Takayama, T., Falo, L.D., & Thomson, A.W. (2001). Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood, 98(5), 1512-1523.American Society of Hematology. doi: 10.1182/blood.v98.5.1512.
  • Whitmore, M.M., Li, S., Falo, L.J., & Huang, L. (2001). Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. CANCER IMMUNOLOGY IMMUNOTHERAPY, 50(10), 503-514. doi: 10.1007/s002620100227.
  • Wu, X., He, Y., Falo, L.D., Hui, K.M., & Huang, L. (2001). Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol Ther, 3(3), 368-374.Elsevier. doi: 10.1006/mthe.2001.0280.
  • Barratt-Boyes, S.M., Zimmer, M.I., Harshyne, L.A., Meyer, E.M., Watkins, S.C., Capuano, S., Murphey-Corb, M., Falo, L.D., & Donnenberg, A.D. (2000). Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol, 164(5), 2487-2495.Oxford University Press (OUP). doi: 10.4049/jimmunol.164.5.2487.
  • He, Y., Pimenov, A.A., Nayak, J.V., Plowey, J., Falo, L.D., & Huang, L. (2000). Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther, 11(4), 547-554.SAGE Publications. doi: 10.1089/10430340050015734.
  • Larregina, A.T., & Falo, L.D. (2000). Generating and regulating immune responses through cutaneous gene delivery. Hum Gene Ther, 11(16), 2301-2305.SAGE Publications. doi: 10.1089/104303400750035852.
  • Morelli, A.E., Larregina, A.T., Ganster, R.W., Zahorchak, A.F., Plowey, J.M., Takayama, T., Logar, A.J., Robbins, P.D., Falo, L.D., & Thomson, A.W. (2000). Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol, 74(20), 9617-9628.American Society for Microbiology. doi: 10.1128/jvi.74.20.9617-9628.2000.
  • Tüting, T., Austyn, J., Storkus, W.J., & Falo, L.D. (2000). The immunology of DNA vaccines. Methods Mol Med, 29, 37-64.Springer Nature. doi: 10.1385/1-59259-688-6:37.
  • Falo, L.D. (1999). Targeting the skin for genetic immunization. Proc Assoc Am Physicians, 111(3), 211-219.Wiley. doi: 10.1046/j.1525-1381.1999.99227.x.
  • Hammond, S.A., Cook, S.J., Falo, L.D., Issel, C.J., & Montelaro, R.C. (1999). A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology, 254(1), 37-49.Elsevier. doi: 10.1006/viro.1998.9550.
  • Nayak, J.V., & Falo, L.D. (1999). Antigen delivery to dendritic cells: Implications for cancer immunotherapy. Clinical and Applied Immunology Reviews, 19(10-11), 131-135.Elsevier. doi: 10.1016/s0197-1859(00)87087-9.
  • Celluzzi, C.M., & Falo, L.D. (1998). Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol, 160(7), 3081-3085.Oxford University Press (OUP). doi: 10.4049/jimmunol.160.7.3081.
  • Celluzzi, C.M., & Falo, L.D. (1998). Gutting edge: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. Journal of Immunology, 160(7), 3081-3085.
  • Deng, J.S., Falo, L.D., Kim, B., & Abell, E. (1998). Cytotoxic T cells in basal cell carcinomas of skin. Am J Dermatopathol, 20(2), 143-146.Wolters Kluwer. doi: 10.1097/00000372-199804000-00007.
  • Falo, L.D., & Storkus, W.J. (1998). Giving DNA vaccines a helping hand. Nat Med, 4(11), 1239-1240.Springer Nature. doi: 10.1038/3217.
  • Ling, M.R., Swinyer, L.J., Jarratt, M.T., Falo, L., Monroe, E.W., Tharp, M., Kalivas, J., Weinstein, G.D., Asarch, R.G., Drake, L., Martin, A.G., Leyden, J.J., Cook, J., Pariser, D.M., Pariser, R., Thiers, B.H., Lebwohl, M.G., Babel, D., Stewart, D.M., Eaglstein, W.H., Falanga, V., Katz, H.I., Bergfeld, W.F., Hanifin, J.M., & Young, M.R. (1998). Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol, 38(6 Pt 2), S95-102.Elsevier. doi: 10.1016/s0190-9622(98)70492-x.
  • Tüting, T., Storkus, W.J., & Falo, L.D. (1998). DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol, 111(2), 183-188.Elsevier. doi: 10.1046/j.1523-1747.1998.00261.x.
  • Celluzzi, C.M., & Falo, L.D. (1997). Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol, 108(5), 716-720.Elsevier. doi: 10.1111/1523-1747.ep12292095.
  • Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., & Falo, L.D. (1996). Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 183(1), 283-287.Rockefeller University Press. doi: 10.1084/jem.183.1.283.
  • Condon, C., Watkins, S.C., Celluzzi, C.M., Thompson, K., & Falo, L.D. (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat Med, 2(10), 1122-1128.Springer Nature. doi: 10.1038/nm1096-1122.
  • González, S., Vibhagool, C., Falo, L.D., Momtaz, K.T., Grevelink, J., & González, E. (1996). Treatment of pyogenic granulomas with the 585 nm pulsed dye laser. J Am Acad Dermatol, 35(3 Pt 1), 428-431.Elsevier. doi: 10.1016/s0190-9622(96)90610-6.
  • Kress, D.W., Seraly, M.P., Falo, L., Kim, B., Jegasothy, B.V., & Cohen, B. (1996). Olmsted syndrome. Case report and identification of a keratin abnormality. Arch Dermatol, 132(7), 797-800.American Medical Association (AMA). doi: 10.1001/archderm.132.7.797.
  • Falo, L.D., Kovacsovics-Bankowski, M., Thompson, K., & Rock, K.L. (1995). Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med, 1(7), 649-653.Springer Nature. doi: 10.1038/nm0795-649.
  • Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., & Deleo, A.B. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med, 1(12), 1297-1302.Springer Nature. doi: 10.1038/nm1295-1297.
  • Falo, L.D., Sober, A.J., & Barnhill, R.L. (1994). Evolution of a naevus spilus. Dermatology, 189(4), 382-383.Karger Publishers. doi: 10.1159/000246884.
  • Razi-Wolf, Z., Falo, L.D., & Reiser, H. (1994). Expression and function of the costimulatory molecule B7 on murine Langerhans cells: evidence for an alternative CTLA-4 ligand. Eur J Immunol, 24(4), 805-811.Wiley. doi: 10.1002/eji.1830240405.
  • Falo, L.D., Colarusso, L.J., Benacerraf, B., & Rock, K.L. (1992). Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci U S A, 89(17), 8347-8350.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.89.17.8347.
  • Williams, W.W., Falo, L.D., Lu, C.Y., Benacerraf, B., & Sy, M.S. (1988). Effects of in vivo monoclonal anti-I-A antibody treatment in neonatal mice on intrathymic and peripheral class II antigen expression. Cell Immunol, 111(1), 126-138.Elsevier. doi: 10.1016/0008-8749(88)90057-3.
  • Falo, L.D., Benacerraf, B., Rothstein, L., & Rock, K.L. (1987). Cerulenin is a potent inhibitor of antigen processing by antigen-presenting cells. J Immunol, 139(12), 3918-3923.Oxford University Press (OUP). doi: 10.4049/jimmunol.139.12.3918.
  • Falo, L.D., Haber, S.I., Herrmann, S., Benacerraf, B., & Rock, K.L. (1987). Characterization of antigen association with accessory cells: specific removal of processed antigens from the cell surface by phospholipases. Proc Natl Acad Sci U S A, 84(2), 522-526.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.84.2.522.
  • Falo, L.D., Benacerraf, B., & Rock, K.L. (1986). Phospholipase treatment of accessory cells that have been exposed to antigen selectively inhibits antigen-specific Ia-restricted, but not allospecific, stimulation of T lymphocytes. Proc Natl Acad Sci U S A, 83(18), 6994-6997.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.83.18.6994.
  • ROCK, K.L., FALO, L.D., ABBAS, A.K., & BENACERRAF, B. (1986). PROCESSING AND PRESENTATION OF ANTIGENS TO MHC-RESTRICTED LYMPHOCYTES-T. ANNALES DE L INSTITUT PASTEUR-IMMUNOLOGY, D137(2), 300-303.
  • Falo, L.D., Sullivan, K., Benacerraf, B., Mescher, M.F., & Rock, K.L. (1985). Analysis of antigen presentation by metabolically inactive accessory cells and their isolated membranes. Proc Natl Acad Sci U S A, 82(19), 6647-6651.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.82.19.6647.

  • Friedman, B., Donahue, C., Erdos, G., & Falo, L.D. (2016). A topical chemo-immunotherapy for squamous cell carcinoma. In JOURNAL OF IMMUNOLOGY, 196.
  • Korkmaz, E., Friedrich, E.E., Erdos, G., Falo, L.D.J., Galiano, R.D., Mustoe, T.A., Hong, S.J., & Ozdoganlar, B. (2016). Enhanced Cutaneous Delivery of Polymer Complexed Dicer-Substrate Short Interfering RNAs using Carboxymethyl Cellulose-Based Dissolvable Microneedle Arrays for Effective Knockdown of Targeted Gene Expression. In TISSUE ENGINEERING PART A, 22, (p. S27).
  • Sumpter, T.L., Tkacheva, O., Falo, L.D., & Larregina, A.T. (2016). Neurokinin A reduces FccRI-triggered inflammation mediated by cutaneous mast cells. In JOURNAL OF IMMUNOLOGY, 196.
  • Sumpter, T.L., Tkacheva, O., Shufesky, W., Falo, L.D., Morelli, A.E., & Larregina, A.T. (2016). Hemokinin-1 and Substance P provide adjuvancy for T cell activation and survival necessary for innate and adaptive cellular immune responses. In JOURNAL OF IMMUNOLOGY, 196(1_Supplement).Oxford University Press (OUP). doi: 10.4049/jimmunol.196.supp.129.8.
  • Brand, R., Erdos, G., Epperly, M., Dixon, T., Franicola, D., Falo, L.D.J., Wipf, P., & Greenberger, J.S. (2015). Effective Topical Delivery of Radiomitigator GS-Nitroxide (JP4-039) by Microneedle Arrays. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3), (pp. E541-E542).Elsevier. doi: 10.1016/j.ijrobp.2015.07.1934.
  • Brand, R.M., Paglia, M., & Falo, L.D. (2015). Psoriasis severity is increased by alcohol abuse: An animal model of alcohol abuse and psoriasis. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 135, (p. S69).
  • Friedman, B.E., Carey, C., & Falo, L.D. (2015). Induction of skin resident and systemic T-cell immunity by cutaneous immunization using dissolvable microneedle arrays. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 135, (p. S6).
  • Zhang, Y., Falo, L.D., & You, Z. (2015). Cutaneous genetic vaccination targeting dermal DC subsets for enhanced antitumor immunity. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 135, (p. S6).
  • Brand, R.M., Paglia, M.C., & Falo, L.D. (2014). Alcohol consumption amplifies immune suppression induced by ultraviolet radiation. In ALCOHOL, 48(7), (p. 728).Elsevier. doi: 10.1016/j.alcohol.2014.09.007.
  • Brand, R.M., Paglia, M.C., & Falo, L.D.J. (2014). ALCOHOL CONSUMPTION INCREASES THE SEVERITY OF PSORIASIS. In ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 38, (p. 238A).
  • Korkmaz, E., Friedrich, E.E., Erdos, G., Mathers, A., Falo, L.D.J., Ozdoganlar, B., & Washburn, N.R. (2014). Microneedle Array-Mediated Intradermal Delivery of Tumor Necrosis Factor-Alpha-Inhibitors. In TISSUE ENGINEERING PART A, 20, (p. S59).
  • Brand, R.M., Stottlemyer, J.M., & Falo, L.D.J. (2013). ALCOHOL INDUCED IMMUNE SUPPRESSION RESULTS IN PART FROM IMMUNE SKEWING THAT CAN BE OVERCOME BY ADJUVANT. In ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 37, (p. 168A).
  • Brand, R.M., Stottlemyer, J.M., Paglia, M.C., & Falo, L.D.J. (2013). Alcohol consumption amplifies immune suppression induced by ultraviolet radiation. In ALCOHOL, 47(7), (p. 568).Elsevier. doi: 10.1016/j.alcohol.2013.09.008.
  • Dulmage, B.O., Falo, L.D., & Geskin, L.J. (2013). Romidepsin, but not Pralatrexate, alters expression of a genetic signature in CTCL. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 133, (p. S68).
  • Schowalter, M.K., Ho, J., Dulmage, B.O., Falo, L.D., & Geskin, L.J. (2013). Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading melanoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 133, (p. S237).
  • Brand, R., Stottlemyer, J., & Falo, L.D.J. (2012). Alcohol consumption inhibits Th1-skewed CHS responses independent of hapten strength. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S100).
  • Brand, R.M., Stottlemyer, J.M., Cline, R.A., & Falo, L.D.J. (2012). Ethanol-induced systemic immune dysfunction does not correlate with oxidative stress in the liver. In ALCOHOL, 46(2), (p. 174).
  • Erdos, G., Donahue, C., Zhang, J., Gambotto, A., Ozdoganlar, B.O., & Falo, L.D. (2012). Dissolvable microneedle arrays enable delivery of live adenovectors to the skin for cutaneous transduction and genetic immunization. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S105).
  • O'Neill, B.L., Mirvish, E., Pomerantz, R., Falo, L.D., & Geskin, L.J. (2012). TOX, PLS3, and KIR3DL2 genes are differentially expressed in Sezary Syndrome. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S25).
  • Schowalter, M.K., Akilov, O.E., Falo, L.D., & Geskin, L.J. (2012). Reduced myeloid-derived suppressor cell function is associated with interferon therapy of cutaneous T-cell lymphoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S106).
  • Toussaint, H., Narciso, J.T., Erdos, G., Larregina, A.T., Donahue, C., & Falo, L.D. (2012). Poly(dG) particulate vaccines target and activate skin antigen presenting cells to induce potent immunity in vivo. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S106).
  • Akilov, O.F., Yeh, P.E., Hood, B., Conrads, T.P., Falo, L.D., & Geskin, L.J. (2011). Autoantibody to HSC70 in patients with tumor stage of mycosis fungoides. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S102).
  • Brand, R., Epperly, M., Stottlemyer, J., Cline, R., Kim, H., Gao, X., Li, S., Huq, S., Wipf, P., Kagan, V., Greenberger, J., & Falo, L.D. (2011). The GS-nitroxide JP4-039 is a potent topical antioxidant that mitigates skin damage from ionizing radiation. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S117).
  • Erdos, G., Donahue, C., Zhang, J., Ozdoganlar, B., Gambotto, A., & Falo, L.D. (2011). Effective preservation and skin delivery of biologically active cargo including live viruses by dissolvable microneedle arrays (MNAs). In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S65).
  • Geskin, L.J., Akilov, O.E., Linzer, D.E., Lin, Y., Falo, L.D., & Lokshin, A.E. (2011). Age-matched multiplex analysis reveals global immune dysregulation in patients with CTCL. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S92).
  • Huen, A.C., Falo, L.D., & Wells, A. (2011). EXPRESSION OF CXCL11 IN RE-DIFFERENTIATING KERATINOCYTES. In WOUND REPAIR AND REGENERATION, 19(2), (p. A27).
  • Mirvish, E.D., Feng, H., Pomerantz, R.G., Falo, L.D., Chang, Y., Moore, P.S., & Geskin, L.J. (2011). Digital transcriptome subtraction for pathogen sequence detection and gene expression profiling in CTCL. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S28).
  • Pomerantz, R.G., Mirvish, E.D., Patton, T.J., Falo, L.D., & Geskin, L.J. (2011). Disease stage-related decreases in distinct superantigen-related T cell receptor-Vβs in cutaneous T-cell lymphoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131, (p. S28).
  • Brand, R.M., Epperly, M., Stottlemyer, J., Gao, X., Li, S., Huq, S., Wipf, P., Kagan, V., Greenberger, J., & Falo, L.D. (2010). The GS-nitroxide JP04-39 is a potent topical antioxidant that can mitigate skin damage from ionizing radiation. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 130, (p. S136).
  • Epperly, M., Brand, R., Stottlemyer, J., Dixon, T.M., Gao, X., Li, S., Huq, S., Wipf, P., Falo, L.D., & Greenberger, J.S. (2010). Topical Application of GS-Nitroxide JP4-039 Emulsion Mitigates Ionizing Irradiation Induced Skin Burns. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), (pp. S634-S635).Elsevier. doi: 10.1016/j.ijrobp.2010.07.1478.
  • Geskin, L.J., Akilov, O.E., Butterfield, I., Whiteside, T.L., & Falo, L.D. (2010). Patient-specific dendritic cell immunization against tumor in Sezary syndrome. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 130, (p. S56).
  • Brand, R., Epperly, M., Radfar, A., Dodd, N.R., Gao, X., Li, S., Huq, S., Jukic, D., Wipf, P., Kagan, V., Greenberger, J.S., & Falo, L.D. (2009). Topical application of novel mitochondrial antioxidants mitigates skin damage from ionizing radiation. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129, (p. S115).
  • Brand, R.M., & Falo, L.D. (2009). Ethanol triggered immune dysfunction is dependent on immunization method. In ALCOHOL, 43(8), (p. 666).Elsevier. doi: 10.1016/j.alcohol.2009.09.006.
  • Brand, R.M., Donahue, C., Miller, M., Plowey, J., & Falo, L.D. (2009). Alcohol consumption induces regional immune dysfunction. In JOURNAL OF IMMUNOLOGY, 182.
  • Erdos, G., Toussaint, H., Williams, M., Ozdoganlar, B.O., & Falo, L.D.J. (2009). Topical patch vaccines target antigen to cutaneous dendritic cells efficiently inducing potent cell mediated immune responses. In JOURNAL OF IMMUNOLOGY, 182.
  • Erdos, G., Toussaint, H., Williams, M., Zhang, J., Ozdoganlar, B.O., & Falo, L.D. (2009). Dissolving microneedle arrays effectively deliver soluble and particulate biologically active molecules into the skin. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129, (p. S117).
  • Geskin, L.J., Kirkwood, J., Butterfield, L., Storkus, W., Whiteside, T., & Falo, L.D. (2009). Evaluation of antigen loading strategies for dendritic cell vaccines in patients with metastatic melanoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129, (p. S117).
  • Pomerantz, R.G., Mirvish, E.D., Erdos, G., Donnenberg, A.D., Falo, L.D.J., & Geskin, L.J. (2009). Novel approach to genomic profiling in Sezary Syndrome. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129, (p. S29).
  • Pomerantz, R.G., Patton, T.J.J., Donnenberg, A.D., Mirvishi, E.D., Falo, L.D.J., & Geskin, L.J. (2009). Disease stage-related changes in T cell receptor-VB profile in cutaneous T cell lymphoma. In JOURNAL OF IMMUNOLOGY, 182.
  • Toussaint, H., Erdos, G., & Falo, L.D.J. (2009). Targeted delivery of Poly(dG) conjugated protein antigens to antigen presenting cells results in efficient cross-priming in vivo. In JOURNAL OF IMMUNOLOGY, 182.
  • Liu, Z., Noh, H.S., Chen, J., Kim, J.H., Falo, L.D.J., & You, Z. (2008). Tumor Treg Potently Abrogate In Vivo Antitumor T Cell Priming. In JOURNAL OF IMMUNOTHERAPY, 31(9), (p. 966).
  • He, Y., Zhang, J., Donahue, C., & Falo, L.D. (2007). Migrating skin DCs play a dominant role in T cell priming in recombinant viral vector mediated genetic immunization. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 127, (p. S127).
  • Liu, Z., Noh, H.S., Falo, L.D.J., Sakaguchi, S., & You, Z. (2007). GITR Ligation and CD4+ T-cell combination therapy eradicates an aggressive solid tumor by concomitantly enhancing antitumor immunity while inhibiting treg suppressive activity. In JOURNAL OF IMMUNOTHERAPY, 30(8), (pp. 873-874).
  • Liu, Z., Noh, H.S., Kim, J.H., Chen, J., Falo, L.D.J., & You, Z. (2007). Elevated FoxP3+CD4+ CD25+ regulatory T cells in tumor-bearing mice suppress T-cell priming, effector-cell function and anti-tumor immunity. In JOURNAL OF IMMUNOTHERAPY, 30(8), (p. 880).
  • Mathers, A., Morelli, A.E., Janelsins, B., Rubin, J.P., Tkacheva, O.A., Falo, L.D., & Larregina, A.T. (2007). Migratory dendritic cells from human skin stimulate th1 and th17 allogeneic responses relevant for the rejection of cutaneous allografts. In AMERICAN JOURNAL OF TRANSPLANTATION, 7, (p. 415).
  • Geskin, L., Kwon, S., Patton, T., McCann, S., Paley, K., & Falo, L.D.J. (2006). Evaluation of CD25-targeting approaches for Treg depletion in CTCL. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, (p. 121).
  • Geskin, L.J., Kwon, S.Y., Strauss, L., Whiteside, T., Watkins, S., & Falo Jr, L.D. (2006). Targeting CD25 for T-Regulatory cell depletion in cutaneous T-Cell lymphoma. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, (p. 48).
  • He, Y., Zhang, J., Donahue, C., & Falo, L.D. (2006). Skin derived dendritic cells play a dominant role in priming naive T cells after genetic immunization using lentiviral vectors. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, (p. 119).
  • Kwon, S., Geskin, L., Patton, T., McCann, S., Paley, K., & Falo, L.D.J. (2006). CTCL patients exhibit elevated levels of regulatory T-cells that correspond with disease severity and response to therapy. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, (p. 111).
  • Ferris, L., & Falo, L.D. (2005). Activation phenotype of human dendritic cells induced by human β-defensins 3. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 124(4), (p. A116).
  • Geskin, L.J., Kingston, A.A., Dixon, K., Kalinski, P., Whiteside, T., & Falo, L.D. (2005). Dendritic cell-based immumotherapy for cutaneous T-cell lymphoma (CTCL). In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 125(1), (p. A4).
  • He, Y., Zhang, J., & Falo, L.D. (2005). Transduction of dendritic cell subsets by lentivector in vivo leads to induction of strong and long-lasting T cell-mediated antigen specific immunity. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 124(4), (p. A114).
  • Morelli, A.E., Rubin, P., Erdos, G., Tkacheva, O.A., Zahorchack, A., Thomson, A.W., Falo, L.D., & Larregina, A.T. (2005). Distinct subsets of skin dendritic cells induce similar T helper responses. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 124(4), (p. A122).
  • He, Y.K., Zhang, J.Y., Mi, Z.B., Robbins, P.D., & Falo, L.D. (2004). Lentiviral mediated transduction of dendritic cell progenitors does not alter the maturation and antigen presentation function of dendritic cells. In FASEB JOURNAL, 18(4), (p. A61).
  • Hokey, D., Geskin, L., & Falo, L.D. (2002). Differential MHC class I presentation of cytosolic and membrane-bound tumor antigens by dendritic cells. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 119(1), (p. 306).
  • Björck, P., Falo, L.D., & Storkus, W.J. (2001). Anti-tumor effect and generation of tumor-specific CD8+ T-cells after combined Flt3L and GM-CSF mobilization and dendritic cell therapy. In FASEB JOURNAL, 15(5), (p. A1200).
  • Larregina, A.T., Morelli, A.E., Spencer, L.A., Watkins, S.C., Thomson, A.W., & Falo, L.D. (2001). CD14+ CD1a- dermal migratory cells acquire the characteristics of Langerhans after short-term culture in GM-CSF, TGFβ-1 and IL-4. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(4), (p. 1004).
  • Larregina, A.T., Watkins, S.C., Erdos, G., Spencer, L.A., Stolz, D.B., Storkus, W.J., & Falo, L.D. (2001). Direct transfection and activation of human Langerhans cells in situ using biolistic delivery of naked DNA. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(4), (p. 1016).
  • Morel, P.A., Falkner, D., Plowey, J., & Falo, L.D. (2001). The cellular localization of expressed protein and route of DNA immunization influences the nature and magnitude of the immune response. In FASEB JOURNAL, 15(4), (p. A652).
  • Björck, P., Falo, L.D., & Storkus, W.J. (2000). Combined Flt3L and GM-CSF mobilization enhance the frequencies of DC subsets exhibiting differential functional capabilities. In FASEB JOURNAL, 14(6), (p. A1132).
  • Björck, P., Falo, L.D., & Storkus, W.J. (2000). Generation of CD19+CD11c+ dendritic cells in vivo after combined Flt3L and GM-CSF mobilization. In FASEB JOURNAL, 14(6), (p. A1050).
  • Dong, X., Nayak, J., Falo, L.D., & Salter, R.D. (2000). Comparison of routes of antigen uptake, processing and presentation by human monocyte-derived dendritic cells. In FASEB JOURNAL, 14(6), (p. A1051).
  • Morelli, A.E., Larregina, A.T., Zahorchak, A., Plowey, J.M., Takayama, T., Logar, A.J., Robbins, P.D., Falo, L.D., & Thomson, A.W. (2000). Impact of recombinant adenovirus on dendritic cell (DC) maturation and function: Implications for genetic engineering of DC for anti-rejection therapy. In TRANSPLANTATION, 69(8), (p. S352).Wolters Kluwer. doi: 10.1097/00007890-200004271-00928.
  • Larregina, A., & Falo, L.D. (1999). Gene delivery to dendritic cells in human skin. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 112(4), (p. 598).
  • Lyon, R.T., Veith, F.J., Bolton, L., & Machado, F. (1998). Clinical benchmark for healing of chronic venous ulcers. Venous Ulcer Study Collaborators. In Am J Surg, 176(2), (pp. 172-175).Elsevier.United States. doi: 10.1016/s0002-9610(98)00136-6.
  • Celluzzi, C.M., & Falo, L.D. (1997). Immunization with dendritic cells fused with tumor cells elicits potent tumor specific immunity. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 157).
  • Condon, C., Thompson, K., & Falo, L.D. (1997). Internalization, processing, and MHC class I restricted presentation of particulate antigens by keratinocytes. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 5).
  • Geskin, L.J., Celluzzi, C.M., & Falo, L.D. (1997). In vivo trafficking of adoptively transferred dendritic cells. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 438).
  • Rau, K., Plowey, J., & Falo, L.D. (1997). Adoptive transfer of bone-marrow derived dendritic cells induces hapten-specific contact hypersensitivity. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 308).
  • Celluzzi, C., & Falo, L.D. (1996). Peptide-pulsed epidermal Langerhans cells induce a cytotoxic T lymphocyte (CTL) response in mice. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 106(4), (p. 451).
  • Deng, J.S., Falo, L.D., Kim, B., & Abell, E. (1996). Cytotoxic T cells in skin cancers. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 106(4), (p. 730).
  • Falo, L.D., Condon, C.A., & Thompson, K.A. (1996). Immunization by cutaneous delivery of naked DNA induces CTL mediated, protective tumor immunity. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 106(4), (p. 149).
  • CELLUZZI, C., & FALO, L.D. (1995). INDUCTION OF ANTIGEN-SPECIFIC IMMUNITY OF MELANOMA UTILIZING EPIDERMAL LANGERHANS CELLS IN A MURINE MODEL. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 104(4), (p. 566).
  • CONDON, C.A., & FALO, L.D. (1995). INDUCTION OF ANTIGEN-SPECIFIC MELANOMA IMMUNITY BY BIOBALISTIC GENETIC IMMUNIZATION. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 104(4), (p. 649).
  • KIM, B.K., DENG, I.S., & FALO, L.D. (1995). CORRELATION OF MHC CLASS-I EXPRESSION AND CD8+ T-CELL RESPONSES IN BASAL-CELL CARCINOMA. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 104(4), (p. 649).
  • YEH, E.T.Y., REISER, H., FALO, L.D., DALEY, J., & ROCK, K.L. (1987). LYMPHOCYTE-T TAP EXPRESSION MUTANTS ARE DEFECTIVE IN TRANSMEMBRANE RECEPTOR SIGNALING. In FEDERATION PROCEEDINGS, 46(4), (p. 1497).
  • FALO, L.D., SULLIVAN, K., MESCHER, M.M., BENACERRAF, B., & ROCK, K.L. (1985). MHC-RESTRICTED STIMULATION OF INDUCER T-CELL HYBRIDOMAS BY ISOLATED IA-HEARING MEMBRANES. In FEDERATION PROCEEDINGS, 44(4), (p. 1183).
Research Interests
Immunology Clinical sciences Biochemistry and cell biology Oncology and carcinogenesis Medical biotechnology Medical microbiology
headshot of Louis Falo
Contact Louis Falo
Professor
lof2@pitt.edu
Work: (412) 864-3664